サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1422809

ヒト絨毛性ゴナドトロピン（HCG）市場レポート：技術別、治療領域別、エンドユーザー別、地域別、2024-2032年

Human Chorionic Gonadotropin Market Report by Technology, Therapeutic Area, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 139 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ヒト絨毛性ゴナドトロピン（HCG）市場レポート：技術別、治療領域別、エンドユーザー別、地域別、2024-2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 139 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヒト絨毛性ゴナドトロピン（HCG）の世界市場規模は、2023年に9億7,350万米ドルに達しました。今後、IMARC Groupは、市場が2024年から2032年の間に6.65%の成長率（CAGR）を示し、2032年までに17億6,840万米ドルに達すると予測しています。女性の不妊症の増加、性腺機能低下症関連疾患の有病率の増加、組換え技術を用いたHCGの生産は、市場を牽引する主な要因のいくつかです。

ヒト絨毛性ゴナドトロピン（HCG）は、妊娠中に胎盤の合胞体栄養芽球細胞によって産生される化学物質です。血液、尿、肝臓、結腸、下垂体に含まれます。HCGは黄体を刺激してプロゲステロンを産生させ、妊娠を維持します。イオン交換クロマトグラフィー、色素親和性クロマトグラフィー、ナノろ過、逆相高速液体クロマトグラフィー（HPLC）などのさまざまな技術を用いて、臨床応用のために妊婦の尿から抽出・精製されます。HCGは、不妊症の治療、妊娠の可能性の増大、テストステロンと精子の生成の補助、男子小児の陰睾の治療などに広く使用されています。また、妊娠関連障害、出生前スクリーニング、および婦人科がんの診断とモニタリングにも役立ちます。

ヒト絨毛性ゴナドトロピン（HCG）市場動向：

子宮障害、卵管閉塞、多嚢胞性卵巣症候群（PCOS）、内分泌系障害などによる女性の不妊症の増加が、市場成長を促進する主な要因の一つです。HCGは、体外受精（IVF）や子宮内人工授精（IUI）などの様々な生殖補助技術において、排卵誘発を補助し、胚の形成を促進し、卵子採取の正しいタイミングを容易にし、子宮内膜の厚さを増加させ、子宮内膜の受容性を改善することから、女性の不妊症を治療するために広く使用されています。これに加えて、女性の妊娠の可能性を高めるために、他の不妊治療薬との併用が広まっていることも、別の成長促進要因として作用しています。さらに、肥満や2型糖尿病を患う男性における性腺機能低下症関連疾患の有病率の増加により、テストステロンレベルの改善、生殖能力の強化、性機能の促進を目的としたHCGの応用が増加していることも、市場の成長を後押ししています。さらに、天然由来のHCGと比較して、同一の特性、強化された有効性、改善された安全性を提供し、患者の耐性を高める組換え技術を使用したHCGの生産は、市場の成長にプラスの影響を与えています。その他の要因としては、医療インフラの急速な発展、不妊に関する治療やサービスの利用可能性の増加、高齢者人口の増加、新しい精製・抽出技術の発売のための広範な研究開発（R&D）活動、人々の性的健康を改善するための様々な政府イニシアチブの実施などが挙げられ、市場のさらなる成長が見込まれています。

本レポートで扱う主な質問

  • 世界のヒト絨毛性ゴナドトロピン（HCG）市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 世界のヒト絨毛性ゴナドトロピン（HCG）市場における市場促進要因、抑制要因、機会は何か？
  • 主要な地域市場は？
  • 最も魅力的なヒト絨毛性ゴナドトロピン（HCG）市場はどの国か？
  • 技術別の市場内訳は？
  • 治療領域別の市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 世界のヒト絨毛性ゴナドトロピン（HCG）市場の競合構造は？
  • 世界のヒト絨毛性ゴナドトロピン（HCG）市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 ヒト絨毛性ゴナドトロピン（HCG）の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：技術別

  • 自然源抽出
    • 市場動向
    • 市場予測
  • 組換え技術
    • 市場動向
    • 市場予測

第7章 市場内訳：治療領域別

  • 女性不妊治療
    • 市場動向
    • 市場予測
  • 男性性腺機能低下症
    • 市場動向
    • 市場予測
  • 精子減少症治療
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 不妊治療クリニック
    • 市場動向
    • 市場予測
  • 研究機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Biocare Medical LLC
    • Ferring Pharmaceuticals
    • Fresenius SE & Co. KGaA
    • Kamiya Biomedical Company（Nitto Boseki Co. Ltd.）
    • Lee Biosolutions Inc.（Oy Medix Biochemica Ab）
    • Merck & Co. Inc.
    • Prospec-Tany Technogene Ltd.
    • Scripps Laboratories Inc.
    • Sun Pharmaceutical Industries Limited
図表

List of Figures

  • Figure 1: Global: Human Chorionic Gonadotropin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Human Chorionic Gonadotropin Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Human Chorionic Gonadotropin Market: Breakup by Therapeutic Area (in %), 2023
  • Figure 6: Global: Human Chorionic Gonadotropin Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Human Chorionic Gonadotropin Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Human Chorionic Gonadotropin (Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Human Chorionic Gonadotropin (Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Human Chorionic Gonadotropin (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Human Chorionic Gonadotropin (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Human Chorionic Gonadotropin Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Human Chorionic Gonadotropin Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Human Chorionic Gonadotropin Industry: Value Chain Analysis
  • Figure 77: Global: Human Chorionic Gonadotropin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Chorionic Gonadotropin Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
  • Table 4: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Human Chorionic Gonadotropin Market: Competitive Structure
  • Table 7: Global: Human Chorionic Gonadotropin Market: Key Players
目次
Product Code: SR112024A7059

Abstract

The global human chorionic gonadotropin (HCG) market size reached US$ 973.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,768.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.65% during 2024-2032. The rising incidences of infertility in women, increasing prevalence of hypogonadism-related disorders, and production of HCG using recombinant technology represent some of the key factors driving the market.

Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.

Human Chorionic Gonadotropin (HCG) Market Trends:

The rising incidences of infertility among females due to uterine disorders, blocked fallopian tube, polycystic ovarian syndrome (PCOS), and endocrine system disorders are among the key factors driving the market growth. HCG is widely used in various assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility, as it aids in inducing ovulation, promotes the formation of the embryo, facilitates correct timing of oocyte retrieval, increases endometrial thickness, and improve endometrial receptivity. In addition to this, the widespread product utilization in combination with other fertility drugs to increase the chances of pregnancy in women is acting as another growth-inducing factor. Furthermore, the increasing application of HCG to improve testosterone levels, enhance fertility, and promote sexual function due to the increasing prevalence of hypogonadism-related disorders in males suffering from obesity and type 2 diabetes is favoring the market growth. Additionally, the production of HCG using recombinant technology that provides identical properties, enhanced efficacy, and improved safety compared to naturally sourced HCG and enhances patient tolerance is positively influencing the market growth. Other factors, including the rapid development of healthcare infrastructure, increasing availability of treatment and services regarding infertility, rising geriatric population, extensive research and development (R&D) activities for the launch of novel purification and extraction technologies, and the implementation of various government initiatives to improve the sexual health of people, are anticipated to drive the market growth further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global human chorionic gonadotropin (HCG) market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, therapeutic area, and end user.

Technology Insights:

Natural Source Extraction

Recombinant Technology

The report has also provided a detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the technology. This includes natural source extraction and recombinant technology. According to the report, natural source extraction represented the largest segment.

Therapeutic Area Insights:

Female Infertility Treatment

Male Hypogonadism

Oligospermic Treatment

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the therapeutic area has been provided in the report. This includes female infertility treatment, male hypogonadism, oligospermic treatment, and others. According to the report, female infertility treatment accounted for the largest market share.

End User Insights:

Fertility Clinics

Research Institutions

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the end user has been provided in the report. This includes fertility clinics, research institutions, and others. According to the report, fertility clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for human chorionic gonadotropin (HCG). Some of the factors driving the North America human chorionic gonadotropin (HCG) market include rising incidences of infertility among women, growing consumer awareness regarding the available treatment for infertility and gynecological concerns, and rising expenditure capacities of consumers.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global human chorionic gonadotropin (HCG) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc.

Key Questions Answered in This Report:

  • How has the global human chorionic gonadotropin (HCG) market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global human chorionic gonadotropin (HCG) market?
  • What are the key regional markets?
  • Which countries represent the most attractive human chorionic gonadotropin (HCG) markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global human chorionic gonadotropin (HCG) market?
  • Who are the key players/companies in the global human chorionic gonadotropin (HCG) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Chorionic Gonadotropin (HCG) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Natural Source Extraction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Recombinant Technology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Area

  • 7.1 Female Infertility Treatment
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Male Hypogonadism
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oligospermic Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Fertility Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutions
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocare Medical LLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Ferring Pharmaceuticals
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Fresenius SE & Co. KGaA
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Prospec-Tany Technogene Ltd.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Scripps Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sun Pharmaceutical Industries Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis